AbolerIS Pharma established at the Gosselies BioPark

Founded in 2019, AbolerIS Pharma quickly attracted investor interest thanks to its innovative approach to tackling autoimmune, inflammatory and degenerative diseases. The company focuses on developing a monoclonal antibody targeting a novel molecular pathway. This approach aims to inhibit the activity of pathogenic cells and antigen-presenting cells involved in triggering immune responses.

AbolerIS Pharma’s CEO, Ann Meulemans, explains that the company’s therapeutic strategy is designed to rebalance the immune system, thereby preventing it from attacking the body’s own cells. The antibody developed by AbolerIS Pharma shows strong potential to address the needs of patients with rheumatoid arthritis, particularly those who do not respond to current standard anti-TNF treatments. This innovation could enable long-term remission for many patients.

Ann Meulemans, who previously held roles at Johnson & Johnson and Movetis and was involved in the creation of Octimet Oncology, is also co-founder and co-CEO of 2 Bridge, a venture builder supporting the creation of life sciences companies.

A Walloon ecosystem attractive to international biotech companies

The establishment of AbolerIS Pharma at the Gosselies BioPark highlights the strength of Wallonia’s life sciences ecosystem. The region’s scientific expertise and major biopharmaceutical players make Wallonia highly attractive to foreign biotech companies. This new presence further strengthens Wallonia’s position as a leading European biotech hub.